.jpg)
There’s optimism throughout all the markets we serve and to celebrate this we asked our CM Life Science team what they think we can expect from the year ahead in life sciences. Here's what they said...
.jpg)
With such a strong 2019, 2020 was expected to be a ‘mega year’ for life science companies with a reported $1.4 trillion in firepower at their disposal for M&As. However, COVID-19 gave us an unexpected twist.
More and more companies are striving to build diverse and inclusive teams. I wanted to speak to an expert at this, who works within the life sciences arena, to find out what they do.
To gain further insight into how labs have adapted, the CM Life Science team spoke to three North American market leaders in laboratory testing services about how they’ve supported the US healthcare system.
For this episode of CM Conversations, our Director of Operations Tom Maskill spoke with QIAGEN CEO Thierry Bernard.
Consistent early detection is considered the 'holy grail' of cancer diagnosis. If you can catch cancer early enough, you can stop it developing. Liquid biopsy could be the key to unlocking that potential.
.jpg)
The diagnostics space is doing crucial work to detect and limit the spread of Covid-19 all over the world – with companies both big and small contributing to the cause
Rapid detection for sepsis is crucial. Every hour this disease goes untreated, the chances of mortality go up by 8%. To learn more about the disease, we spoke to the experts.
.jpg)
Only 30% of executive positions and 18% of board seats are held by women in biotech. I spoke to industry expert, Melissa Gammell, to find out where we're going wrong, how we get more women into biotech and how we keep them there.
In this episode of CM Conversations, our lab equipment specialist Lucy Smith spoke with Melissa Gammell, Vice President of Business Development at Matphil Technologies about the challenges facing women in biotech.
.jpg)
In this episode, our specialist in the lab equipment space, Lucy Smith, spoke with CEO of Elementar Americas Ryan Titmas. Lucy spoke to Ryan about what it takes to get to the top, as well as some of the lessons he’s learned in his career so far.
As businesses prioritise the wellbeing of their employees, the concept of working a 4 day week is shifting from distant pipedream to reality for a range of organisations around the world.
Even if you’ve been through the process, you may not be aware of exactly what goes into M&A deals. Today, we’ve tried to look into that in a little more detail with Transaction Liability Team Leader Grant Hollis from CFC Underwriting,
When we talk about genomics hubs, then usually we’d be talking about Oxbridge, Boston or Silicon Valley thanks to success stories like 10x Genomics, Illumina or Solexa. However, as the technology needed to conduct genomic R&D becomes more accessible
In the US alone, a report by the Centers for Disease Control and Prevention (CDC) in March this year highlighted how 2.8 million antibiotic-resistant infections occur each year, leading to the deaths of more than 35,000 people.
Coronavirus has provided us with a very large and extremely recent data set for research, patient populations and how different ethnic minorities are being affected versus the research. And the early indicators are that those from minority background
The approach to fighting coronavirus has not differed to the fight against any other outbreak in terms of what is required to control it.
One of the biggest partnering events in the life science calendar Bio-Europe Spring, was scheduled to take place in Paris from March 23 – 27 this year. That all changed with the emergence of COVID-19...
To achieve the WHO's ambitious aim that no woman should die of cervical cancer by 2030 it will take a huge, global effort from companies around the world. Luckily, there is a global community of life sciences companies to help achieve that aim.
To find out more about Bond Health, I spoke to Phil Groom, Commercial Director, and Viktoriya Agova, Marketing Manager from Bond Health to hear how they're connecting the world of lateral flow.
.jpg)
COVID-19 is one of the biggest challenges healthcare has ever faced. Crucial work is being done throughout molecular diagnostics to limit the spread in what many would call the space's finest hour.
Creating a test that's able to identify all autoimmune diseases in one go would be the golden-ticket diagnostic solution – speeding up diagnosis across the board.
There’s so much more to the UK biotech scene than just London and Cambridge. In the North, we're surrounded by many fascinating companies who’re innovating and conducting crucial research.
It's humbling to see how the life science community has come together to combat the coronavirus. Here's what's happening in diagnostics.
.png)
The US remains the largest single-country market in the world for IVD. Here are five companies you need to watch out for.
.png)
While it remains the fourth most common type of cancer for women worldwide, cervical cancer is one of the most preventable and curable with early diagnosis. Let's raise awareness and get more women around the world screened.
Reported to correct 89% of pathogenic human gene variants, prime gene editing has the potential to target over 75,000 different mutations in treatment.
A new generation of start-ups are revolutionising cancer diagnosis, detecting disease before patients even show symptoms with liquid biopsy tests. This innovation is rife in the US.
I’ve lost count of the times I’ve seen ‘PhD preferred’, while recruiting for positions in R&D and product development. In the modern life science talent market, are PhDs really so important?
I’ve lost count of the times I’ve seen ‘PhD preferred’, while recruiting for positions in R&D and product development. In the modern life science talent market, are PhDs really so important?
Globally, sepsis takes six million lives each year. It causes more deaths than breast cancer, lung cancer and stroke combined. Here are five diagnostics companies combating this ugly statistic.
There are countless benefits to companion diagnostics including better evidence of clinical utility & greater patient access, more efficient use of resources, better safety and economic advantages for drug companies.
In today's hyper-connected world, what's the point of conferences? Our Associate Director Jack Shute asked experts from across the speciality chemical space and some of his CM Life Science colleagues to find out.
Product launches and many fascinating, innovative approaches to diagnostics meant that the 71st meeting of the American Association for Clinical Chemistry did not disappoint.
It’s hard to estimate the total size and value of the diagnostics market, however by looking at some of the forecasts available, the scale of the industry is evident.
Cancer doesn’t always make itself known when it presents itself inside a person. People can live with the disease for a long time and, when symptoms manifest, it can be too late as the cancer has become advanced or has spread.
In the world of in vitro diagnostics, there’s nowhere more exciting than Asia. To put it into context, in the period between 2017 and 2022, the North American IVD market is expected to grow from $31.1B to $36.9B,but the Asian market over the same...
Traumatic brain injury (TBI) is a frightening prospect. What makes the prospect more unnerving is that mild TBI like concussion can be very difficult to diagnose, meaning that it can be difficult to devise treatment plans for the condition.
Everyone is always developing the next big thing in diagnostics. Whether it’s a blood test to identify a disease earlier than ever, or a point-of-care device that might save thousands of lives in a rural area, the whole market is constantly evolving.
Collaborations can produce amazing results. When the Wright Brothers put their heads together, they learned how to fly. When Lennon and McCartney met in 1957, pop music was changed forever.
There aren’t many sectors of industry that have seen as much progress in the last 20 years as molecular diagnostics. Point of care testing has, in some cases, eliminated the need for samples to be sent off to labs, enabling physicians to obtain near-
Globally, nearly 1 in 6 people die from cancer. In 2015 alone, the disease was responsible for 8.8 million deaths – the equivalent of the entire population of London.
The value of the point-of-care (POC) diagnostics market has been steadily increasing for the past 40 years, but we’ve seen exponential growth in the last 2. POC analysis offers several advantages to laboratory-based tests, given that they are norm...
